Type 1 diabetic neuropathy and C-peptide

Area of Science:

• Endocrinology and Metabolism
• Neuroscience
• Diabetology

Background:

• Diabetic peripheral polyneuropathy (DPN) is a common complication, disproportionately affecting type 1 diabetes patients.
• Pathogenesis and clinical presentation of DPN differ between type 1 and type 2 diabetes.
• Impaired insulin/C-peptide action is a key factor in type 1 DPN.

Purpose of the Study:

• To investigate the role of C-peptide in preventing and treating DPN in type 1 diabetes.
• To explore the insulin-like, glucose-independent effects of C-peptide on nerve function.

Main Methods:

• Review of preclinical studies on C-peptide's effects on Na+,K+-ATPase, eNOS, and endoneurial blood flow.
• Analysis of C-peptide's regulatory effects on neurotrophic factors and apoptotic pathways.
• Evaluation of animal studies demonstrating C-peptide's impact on nerve conduction and structure.
• Assessment of limited clinical trials in type 1 DPN patients.

Main Results:

• C-peptide exhibits dose-dependent beneficial effects on nerve function and structure in preclinical models.
• It improves nerve conduction, prevents degenerative changes, and promotes nerve regeneration.
• C-peptide modulates neurotrophic factors and apoptosis in the diabetic nervous system.
• Clinical trials suggest C-peptide improves somatic and autonomic nerve function in type 1 DPN.

Conclusions:

• C-peptide replacement therapy shows significant potential for preventing and improving DPN in type 1 diabetes.
• Further large-scale, FDA-approved clinical trials are warranted to establish C-peptide as a treatment.
• C-peptide represents a promising therapeutic avenue for a growing global population with type 1 diabetes.